Credit Suisse analyst Judah Frommer raised the firm’s price target on Avidity Biosciences to $35 from $33 and keeps an Outperform rating on the shares. The analyst said the company provided a "largely positive" interim update of the MARINA Phase 1/2 trial that appears to confirm ‘1001’s activity in the nucleus. Frommer added that splicing changes are a step forward as a key biomarker and that the data underscore the potential of the platform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RNA:
- Avidity Biosciences Stock Soars after Positive RNA Data
- Avidity Biosciences announces results from Phase 1/2 MARINA trial
- Credit Suisse to hold a conference
- Avidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights
- Avidity Biosciences reports Q3 EPS (82c), consensus (93c)